Accreditation Information

Direct Accreditation:

            Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activityfor a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity

Objectives

Identify the prevalence of Lynch syndrome
Identify screening methods used to find patients who carry Lynch syndrome
Identify the incidence of DNA damage repair mutations in pancreas cancer

Target Audience

The primary target audience is Hematology/Oncology and Cancer Center faculty, fellows, students and staff.

Faculty Disclosure

Faculty, Planning Committee and CME Administrator disclosure statement

Sigurdis Haraldsdottir, Speaker, has no relevant financial relationships to disclose

Matthew Kulke, Course Director, consultant for Novartis

Adam Lerner, Co-Course Director, has no relevant financial relationships to disclose

John Sloan, Planning Committee, is a consultant for Oncoquest, Abbvie, and Alexion

George MurphyPlanning Committee,  has no relevant financial relationships to disclose

Sakina Flint, RSS Coordinator, has no relevant financial relationships to disclose

 

Faculty Disclosure of off-label use

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Faculty Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.